Digital speech therapy app for language problems after a recent stroke
Tests a digital speech therapy app alongside usual therapy in adults with post-stroke aphasia.
Key facts
- Who runs it
- Seoul National University Bundang Hospital
- Where
- Seongnam-si and Seoul, South KoreaSee the 3 sites
- Trial code
- Registry title
- Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 10 Dec 2025
- Planned end
- 31 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Zenicog
- Conventional Speech Therapy
- Record updated
- 10 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose speech problem (aphasia) came from a first stroke in the last 3 months. It tests a digital speech therapy app, Zenicom, used with usual speech therapy.
- Age
- 19 years or older
- Sex
- All sexes can join
- Disease stage
- First-ever subacute stroke, within 3 months of onset, confirmed by a CT or MRI scan, with aphasia caused by the stroke and confirmed on the Speech Assessment (PK-WAB-R)
Main reasons for not taking part
- Stroke that is getting worse or is not medically stable
- Other brain or nerve diseases that may affect language
- Serious mental illness needing continuous medication, or dementia
- Current or past alcohol or substance use disorder
- Visual impairment, intellectual disability, or being unable to read and give consent
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 19 years or older
- Confirmed by a specialist to have aphasia caused by a stroke lesion
- First-ever subacute stroke (within 3 months of onset) diagnosed via radiological examination (CT, MRI)
- Diagnosed with aphasia based on the Speech Assessment (PK-WAB-R)
- Whose native language is Korean
Who cannot take part
- Have progressive or hemodynamically unstable stroke
- Having other neurological diseases suspected to affect language ability
- Co-morbid major psychiatric disorders requiring continuous medication (e.g., Major Depressive Disorder, Schizophrenia, Bipolar Disorder, Dementia)
- Co-morbid major neurogenic diseases other than stroke
- Confirmed history of degenerative neuropathy
- Current or past substance or alcohol use disorder
- Visual impairment (Low vision severity: visual acuity of 0.1-0.3 or lower)
- Intellectual disability
- Illiteracy (unable to read and consent)
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Pf. Won Kee Chang, MD, MSTaking people
- Konkuk University Medical CenterSeoul, South KoreaContact: Pf. Won Kee Chang, MD, MSTaking people
- Samsung Medical CenterSeoul, South KoreaContact: Pf. Won Kee Chang, MD, MSTaking people
About the trial
What the trial wants to find out
Clinical Trial Title A Multicenter, Single-Blind, Prospective, Randomized, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of the Digital Therapeutic Device 'Zenicom' for Improving Aphasia in Patients with Subacute Stroke
Read full original descriptionShow less
Clinical Trial Objectives To evaluate the efficacy of the digital therapeutic device Zenicom.
To evaluate the safety of the digital therapeutic device Zenicom.
Clinical Trial Period 6 months from the date of clinical trial plan approval by the Ministry of Food and Drug Safety (MFDS).
Target Condition Patients with aphasia resulting from stroke lesions.
Target Sample Size Total of 20 subjects (10 in the experimental group and 10 in the control group).
Investigational Medical Device Zenicom
Clinical Trial Methodology
1. Device Information
A) Experimental Device: Digital Speech Therapy Application
Group: Performs conventional speech therapy for 30 minutes daily + additional digital speech therapy program during the 2-week treatment period.
B) Control Device: Conventional Speech Therapy
Group: Performs only conventional speech therapy for 30 minutes daily during the 2-week treatment period. 2. Treatment Duration:
Total 2 weeks (10 working days; total usage of 600 minutes or more). 3. Visits:
Total of 3 visits including outpatient and therapy room visits.
Visit 1 (T-1): Screening
Visit 2 (T0): Baseline and Treatment initiation
Visit 3 (T1): Post-treatment assessment
Inclusion and Exclusion Criteria
1. Inclusion Criteria Patients who satisfy all of the following criteria:
Adults aged 19 years or older.
Patients confirmed by a specialist to have aphasia caused by a stroke lesion.
Patients with first-ever subacute stroke (within 3 months of onset) diagnosed via radiological examination (CT, MRI).
Patients diagnosed with aphasia based on the Speech Assessment (PK-WAB-R).
Patients whose native language is Korean.
Patients capable of voluntarily consenting to the study. 2. Exclusion Criteria Patients meeting any of the following criteria will be excluded:
Progressive or hemodynamically unstable stroke.
Patients with other neurological diseases suspected to affect language ability.
Co-morbid major psychiatric disorders requiring continuous medication (e.g., Major Depressive Disorder, Schizophrenia, Bipolar Disorder, Dementia).
Co-morbid major neurogenic diseases other than stroke.
Confirmed history of degenerative neuropathy.
Current or past substance or alcohol use disorder.
Visual impairment (Low vision severity: visual acuity of 0.1-0.3 or lower).
Intellectual disability.
Illiteracy (unable to read and consent).
Patients deemed inappropriate for participation for other reasons.
Refusal to participate in the study.
Suspension and Dropout Criteria
1. Suspension Criteria
If circumstances observed during the trial make it judged unreasonable to continue the study.
Occurrence of Serious Adverse Events (SAE). 2. Dropout Criteria
The subject requests to stop participation or withdraws consent during the trial.
The investigator determines that the subject cannot continue the trial due to adverse events (e.g., headache, eye fatigue, nausea, dizziness, etc.).
The subject arbitrarily takes medication expected to affect the comparative evaluation of the investigational device during the trial.
The dosage of medication that may affect the comparative evaluation of the investigational device is changed during the trial.
Discovery of major protocol violations, such as violation of inclusion/exclusion criteria.
The subject fails to attend scheduled visits and cannot be contacted.
The subject fails to perform the digital speech therapy program for a total of 600 minutes or more.
The investigator determines that the trial should be stopped for other reasons.
Endpoints (Outcome Measures)
1. Primary Efficacy Endpoint
Change in PK-WAB-R scores between T0 and T1 between groups. 2. Secondary Efficacy Endpoints
Change in K-BNT scores between T0 and T1 between groups.
Change in K-SAQOL-12 scores between T0 and T1 between groups.
Statistical Analysis Methods To evaluate the change in PK-WAB-R between T0 and T1 between groups, an independent two-sample test will be used. Depending on the distribution of the change, a parametric method (Student's t-test) or a non-parametric method (Mann-Whitney U test) will be selected and applied.
To evaluate the changes in K-BNT and K-SAQOL-12 between T0 and T1 between groups, an independent two-sample test will be used. Depending on the distribution of the change, a parametric method (Student's t-test) or a non-parametric method (Mann-Whitney U test) will be selected and applied.
The 2 groups in the trial
- Experimental Group: Conventional Speech Therapy + Digital Speech TherapyTreatment being tested
Performs conventional speech therapy for 30 minutes daily + additional digital speech therapy program during the 2-week treatment period.
Treatment: Zenicog and Conventional Speech Therapy
- Control Group: Conventional Speech TherapyExisting treatment, for comparison
Performs only conventional speech therapy for 30 minutes daily during the 2-week treatment period.
Treatment: Conventional Speech Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Safety and Efficacy of the Digital Therapeutic Device Zenicom for Improving Aphasia in Patients With Subacute Stroke and Aphasia (AQ ≥25), a Multicenter, Single-blind, Prospective, Randomized Exploratory Clinical Trial
- Plain-language title
- Digital speech therapy app for language problems after a recent strokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 February 2026